Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 5 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results

Data Visualizations

Phase Distribution

5Total
Early P 1 (1)
P 1 (2)
P 2 (2)

Trial Status

Recruiting3
Active Not Recruiting2

Clinical Trials (5)

Showing 5 of 5 trials
NCT05757700Phase 1Active Not Recruiting

Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma

NCT04512716Early Phase 1Recruiting

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

NCT05583149Phase 2Active Not Recruiting

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

NCT06830031Phase 1Recruiting

Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma

NCT06287398Phase 2Recruiting

Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL

Showing all 5 trials

Research Network

Activity Timeline